MHRA paediatric investigation plan
Approved invented name: Nuvaxovid dispersion for injection, Covid-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2373)
MHRA paediatric investigation plan MHRA-100149-PIP01-21-M01 (update) · Modification
Key facts
| PIP number | MHRA-100149-PIP01-21-M01 (update) |
|---|---|
| Product names | Approved invented name: Nuvaxovid dispersion for injection, Covid-19 Vaccine (recombinant, adjuvanted), Nuvaxovid, Nuvaxovid (Please note that details provided herein specifically relate to Singapore), TBD - Approval not yet granted, Nuvaxovid (Note: PLGB registration, applicable to Great Britain only) |
| Active substances | NVX-CoV2373 |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of coronavirus disease 2019 (COVID-19) |
| Decision | PM: decision on the application for modification of an agreed paediatric investigation plan. |
| Published | Sep 27, 2022 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: